Table 1.

Overview of diagnosis support systems.

Study	N	Decision/Diagnose	Inputs	Outcomes	TRIPOD
(Roach et al. 1994)[25]	282	Low or high risk of LN involvement	PSA,GS, Clinical stage	P LN involvement	79%
(Diaz et al. 1994)[26]	217	Low or high risk of SV involvement	PSA, GS	P SV involvement	69%
(D'Amico et al. 1998)[27]	1872	Patient risk group	PSA, GS, Clinical stage	5-year PSA outcome	72%
(Chang et al. 1999)[28]	43	Localized vs Advanced PCa	PSA, GS, TRUS, DRE	P advanced PCa and P localized PCa	65%
(Roach et al. 2000)[29]	895	Extracapsular extension	PSA, GS	Extracapsular extension risk	92%∗∗
(Lee et al. 2010)[30]	1077	Biopsy	Clinical∗, Imaging∗, PSA	P PCa	86%
(Kim et al. 2011)[31]	532	Advanced PCa	TRUS, Clinical, PSA	P advanced PCa	79%
(Shah et al. 2012)[32]	31	Location PCa	MRI image	Cancer probability map	83%
(Mukai et al. 2013)[33]	30773	PSA test	Clinical	Recommendation	-∗∗∗
(Sadoughi et al. 2014)[34]	360	PCa	PSA, Age	P PCa	33%
(van Leeuwen et al. 2017)[35]	591	Significant PCa	Clinical, PSA, PIRADS, DRE	P significant PCa	97%
(Tosoian, et al. 2017)[36]	4459	Pathological Stage	PSA, GS, Clinical stage	% likelihood of given stage	83%

Abbreviations. N: number of patients; P: probability; PCa: prostate cancer; PSA: prostate specific antigen; PIRADS: Prostate Imaging Reporting and Data System; TRUS: transrectal ultrasound scan; LN: lymph node; GS: Gleason score; SV: seminal vesicles; TRIPOD: adherence to the TRIPOD statement; DRE: digital rectal examination.

^∗Clinical, imaging, and tumor parameters.

^∗∗Abstract only.

^∗∗∗No development or validation of mDSS: no TRIPOD evaluation possible.